These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 14522116)

  • 21. Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting.
    Gupta S; Vyas SP
    J Drug Target; 2007 Apr; 15(3):206-17. PubMed ID: 17454358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and tissue distribution after intravenous administration of a single dose of amphotericin B cochleates, a new lipid-based delivery system.
    Segarra I; Movshin DA; Zarif L
    J Pharm Sci; 2002 Aug; 91(8):1827-37. PubMed ID: 12115810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A nanometer lipid emulsion, lipid nano-sphere (LNS), as a parenteral drug carrier for passive drug targeting.
    Seki J; Sonoke S; Saheki A; Fukui H; Sasaki H; Mayumi T
    Int J Pharm; 2004 Apr; 273(1-2):75-83. PubMed ID: 15010132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats.
    Risovic V; Boyd M; Choo E; Wasan KM
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3339-42. PubMed ID: 14506053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum pharmacology of amphotericin B applied in lipid emulsions.
    Heinemann V; Kähny B; Jehn U; Mühlbayer D; Debus A; Wachholz K; Bosse D; Kolb HJ; Wilmanns W
    Antimicrob Agents Chemother; 1997 Apr; 41(4):728-32. PubMed ID: 9087478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of amphotericin B in serum and tissues in mice treated with amphotericin B-Intralipid.
    Shadkchan Y; Zaslavsky Z; Segal E
    Med Mycol; 2003 Feb; 41(1):15-9. PubMed ID: 12627800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Study of amphotericin B magnetic liposomes for brain targeting.
    Zhao M; Hu J; Zhang L; Zhang L; Sun Y; Ma N; Chen X; Gao Z
    Int J Pharm; 2014 Nov; 475(1-2):9-16. PubMed ID: 25151436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disposition of aerosolized liposomal amphotericin B.
    Lambros MP; Bourne DW; Abbas SA; Johnson DL
    J Pharm Sci; 1997 Sep; 86(9):1066-9. PubMed ID: 9294824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation.
    Gershkovich P; Wasan EK; Lin M; Sivak O; Leon CG; Clement JG; Wasan KM
    J Antimicrob Chemother; 2009 Jul; 64(1):101-8. PubMed ID: 19398459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations.
    Serrano DR; Hernández L; Fleire L; González-Alvarez I; Montoya A; Ballesteros MP; Dea-Ayuela MA; Miró G; Bolás-Fernández F; Torrado JJ
    Int J Pharm; 2013 Apr; 447(1-2):38-46. PubMed ID: 23438978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biodistribution of amphotericin B when delivered through cholesterol hemisuccinate vesicles in normal and A. fumigatus infected mice.
    Saxena S; Ghosh PC
    Pharm Res; 2000 Oct; 17(10):1236-42. PubMed ID: 11145229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating amphotericin B.
    Hossain MA; Maesaki S; Razzaque MS; Tomono K; Taguchi T; Kohno S
    J Antimicrob Chemother; 2000 Aug; 46(2):263-8. PubMed ID: 10933650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ocular amphotericin B delivery by chitosan-modified nanostructured lipid carriers for fungal keratitis-targeted therapy.
    Fu T; Yi J; Lv S; Zhang B
    J Liposome Res; 2017 Sep; 27(3):228-233. PubMed ID: 27601177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatobiliary disposition of liposomal amphotericin B in the isolated perfused rat liver.
    Hong Y; Ramzan I; McLachlan AJ
    J Pharm Sci; 2005 Jan; 94(1):169-76. PubMed ID: 15761940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs.
    Bekersky I; Boswell GW; Hiles R; Fielding RM; Buell D; Walsh TJ
    Pharm Res; 1999 Nov; 16(11):1694-701. PubMed ID: 10571274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the pharmacokinetic profiles of two different amphotericin B formulations in healthy dogs.
    Bingöl B; Bakirel T
    J Vet Pharmacol Ther; 2018 Feb; 41(1):e16-e21. PubMed ID: 28815733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities.
    Ramaswamy M; Peteherych KD; Kennedy AL; Wasan KM
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1184-91. PubMed ID: 11257033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy evaluation of a novel submicron amphotericin B emulsion in murine candidiasis.
    Levy MY; Polacheck I; Barenholz Y; Benita S
    J Med Vet Mycol; 1993; 31(3):207-18. PubMed ID: 8360812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative pharmacokinetics and safety of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and amphotericin B deoxycholate in animal models.
    Brime B; Frutos P; Bringas P; Nieto A; Ballesteros MP; Frutos G
    J Antimicrob Chemother; 2003 Jul; 52(1):103-9. PubMed ID: 12805269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain.
    Shao K; Huang R; Li J; Han L; Ye L; Lou J; Jiang C
    J Control Release; 2010 Oct; 147(1):118-26. PubMed ID: 20609375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.